Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

573 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Screening, risk assessment, and the approach to therapy in patients with prostate cancer.
Freedland SJ. Freedland SJ. Cancer. 2011 Mar 15;117(6):1123-35. doi: 10.1002/cncr.25477. Epub 2010 Oct 19. Cancer. 2011. PMID: 20960523 Review.
Clinical characteristics in black and white men with prostate cancer in an equal access medical center.
Freedland SJ, Sutter ME, Naitoh J, Dorey F, Csathy GS, Aronson WJ. Freedland SJ, et al. Urology. 2000 Mar;55(3):387-90. doi: 10.1016/s0090-4295(99)00461-6. Urology. 2000. PMID: 10699616
Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Freedland SJ, et al. J Urol. 2002 Feb;167(2 Pt 1):516-20. doi: 10.1097/00005392-200202000-00015. J Urol. 2002. PMID: 11792909
Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Freedland SJ, et al. J Urol. 2002 Jul;168(1):110-5. J Urol. 2002. PMID: 12050502
Immunotherapy of prostate cancer.
Freedland SJ, Pantuck AJ, Weider J, Zisman A, Belldegrun AS. Freedland SJ, et al. Curr Urol Rep. 2001 Jun;2(3):242-7. doi: 10.1007/s11934-001-0086-9. Curr Urol Rep. 2001. PMID: 12084272 Review.
Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Freedland SJ, et al. Urology. 2002 Jul;60(1):84-8. doi: 10.1016/s0090-4295(02)01660-6. Urology. 2002. PMID: 12100929
Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
Freedland SJ, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Dorey F, Aronson WJ. Freedland SJ, et al. J Urol. 2003 Mar;169(3):969-73. doi: 10.1097/01.ju.0000051400.85694.bb. J Urol. 2003. PMID: 12576824
Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.
Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Freedland SJ, et al. Urology. 2003 Feb;61(2):365-9. doi: 10.1016/s0090-4295(02)02268-9. Urology. 2003. PMID: 12597949
Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy.
Freedland SJ, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, Aronson WJ. Freedland SJ, et al. J Urol. 2003 Apr;169(4):1325-30. doi: 10.1097/01.ju.0000054004.08958.f3. J Urol. 2003. PMID: 12629353
Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Terris MK; SEARCH Database Study Group. Freedland SJ, et al. Urology. 2003 Apr;61(4):742-7. doi: 10.1016/s0090-4295(02)02525-6. Urology. 2003. PMID: 12670558
573 results
Jump to page
Feedback